anti-EGFR CAR T-cell therapy (Seattle Children's Hospital)

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug Nameanti-EGFR CAR T-cell therapy (Seattle Children's Hospital)
Drug Alias NameEGFR 806CAR(2G)-EGFRt4-1BBz EGFR806-EGFRtEGFR-806
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsImmunostimulantsT lymphocytes stimulants
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursCentral Nervous System NeoplasmsCarcinoma +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeattle Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesCellevolve Bio IncSeattle Children'S Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumoursCentral Nervous System NeoplasmsCarcinoma +[17] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A